Zelluna ASA [ZLNA]: Share capital increase resolution

26 Mar 2025 13:22 CET

Oslo, Norway, 26 March, 2025

Reference is made to the stock exchange notice published on 9 January 2025
regarding an extraordinary general meeting held in Zelluna ASA (the "Company"),
where it was resolved to carry out a reverse share split in the ratio 10:1 and
to grant the Company's board of directors a general authorisation to issue
shares. As the Company's shares cannot be fully divided by 10, the Company's
board of directors has today resolved a share capital increase of NOK 0.70
through the issuance of seven (7) new shares, each with a par value of NOK
0.10, and a subscription price of NOK 2.60 per share.

The shares were subscribed for by Radforsk Investeringsstiftelse. A separate
notification regarding transaction by persons discharging managerial
responsibilities (PDMRs) will be published shortly.

A separate notice with key information regarding the reverse share split will be
published shortly after registration of the share capital increase in the
Norwegian Register of Business Enterprises.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com (mailto:[%20hans.eid@zelluna.com])
Phone: +47 482 48632

About Zelluna ASA
Zelluna's mission is to deliver transformative treatments with the capacity to
cure advanced solid cancers, in a safe and cost-efficient manner, to patients on
a global scale. The Company aims to do this by combining the most powerful
elements of the immune system through pioneering the development of "off the
shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK).
The TCR-NK platform offers a unique mechanism of action with broad cancer
detection capability to overcome the diversity of tumours and will be used "off
the shelf" to overcome scaling limitations of current cell therapies. The lead
program is a world's first MAGE-A4 targeting "off the shelf" TCR-NK for the
treatment of various solid cancers; a pipeline of earlier products follows. The
Company is led by a management team of biotech entrepreneurs with deep
experience in discovery through to clinical development of TCR and cell-based
therapies including marketed products.

More information:
Access the news on Oslo Bors NewsWeb site